BRAF and colorectal carcinoma: Currently, the ESMO clinical practice guidelines recommend dual chemotherapy + bevacizumab for MSS-type BRAF V600E-mutated CRC patients, with triple chemotherapy + bevacizumab being reserved for special circumstances (such as tumors located on the right side).